Abstract
We have assessed the outcome of 66 refractory and relapsed acute leukemia patients treated with high dose mitoxantrone and cytarabine. Therapy consisted of a total dose of 40-60 mg/m2 mitoxantrone and 3 g/m2 of cytarabine daily on 5 consecutive days. A total of 28 patients were treated for primary resistant and 38 patients for early or late relapsed leukemia. A total of 35 patients achieved CR. Four patients died during the induction course. Toxicity was acceptable and comparable to other salvage regimens. The median disease-free and overall survivals were 4 and 6 months, respectively. Although this regimen is effective in achieving remission in refractory leukemia, its duration is short.
Original language | English |
---|---|
Pages (from-to) | 695-700 |
Number of pages | 6 |
Journal | Leukemia Research |
Volume | 23 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1999 |
Externally published | Yes |
Keywords
- Acute leukemia
- HIDAC
- Mitoxantrone
- Refractory
- Relapsed
- Salvage